Phase 2a Study to Evaluate Safety and Explore Efficacy of J2H-1702 for NASH
Status:
RECRUITING
Trial end date:
2025-10-30
Target enrollment:
Participant gender:
Summary
The study aims to evaluate the safety of J2H-1702 compared to the placebo and explore the efficacy of J2H-1702 at Week 12 timepoint after administration compared to baseline in patients with NASH.